From: GDF15 affects venous thrombosis by promoting EndMT through smad2/p-smad2 pathway
 |  | VTE group | Control group |
---|---|---|---|
Leukocyte (109/l) |  | 6.7 ± 3.2 | 6.1 ± 1.1 |
Neutrophil (%) |  | 62.0 ± 16.7 | 56.7 ± 10.2 |
Platelet(109/l) |  | 200.1 ± 60.2 | 184.6 ± 46.6 |
Erythrocyte distribution width (%) |  | 13.1 ± 0.9 | 13.0 ± 0.6 |
Thrombocytocrit (%) |  | 0.20 ± 0.05 | 0.20 ± 0.03 |
Homocysteine (μmol/l) | 18.1 ± 6.7* | 11.6 ± 2.8 | |
hsCRP (mg/l) | Â | 2.8(1.0,42.7)* | 0.6(0.4,0.9) |
CEA (ng/ml) | Â | 2.56(1.51,17.7) | 2.12(1.43,3.10) |
GDF15 (pg/ml) | Â | 568.72(412.66,835.69)* | 299.30(271.00,440.14) |